BACKGROUND: There are limited therapeutic options for treatment-refractory pancreatic ductal adenocarcinoma (PDAC), with a paucity of data to support the best option after progression on gemcitabine-based regimens. The authors performed a metaanalysis to determine the effectiveness of adding oxaliplatin (OX) or various irinotecan formulations to a fluoropyrimidine (FP) after first-line treatment progression in patients with PDAC. METHODS: Different databases, including PubMed, EMBASE, and Cochrane, were searched to identify randomized controlled trials comparing FP monotherapy versus FP combination therapy that included either oxaliplatin (FPOX) or various irinotecan formulations (FPIRI) in patients with PDAC who progressed after first-line treatment. Secondary analyses were planned to assess the effectiveness of FPOX and FPIRI compared with FP. Outcomes of interest included overall survival (OS) and progression-free survival (PFS). RESULTS: Five studies with 895 patients were identified. Patients randomized to receive FPIRI/FPOX had a significantly improved PFS and a trend toward improved OS compared with those who received FP monotherapy. When comparing FPIRI with FP, there was an improvement in both PFS (hazard ratio, 0.64; 95% confidence interval, 0.47-0.87; P 5 .005) and OS (hazard ratio, 0.70; 95% confidence interval, 0.55-0.89; P 5 .004) in patients who received the combination. Conversely, FPOX produced only a modest improvement in PFS with no improvement in OS. CONCLUSIONS: Combination chemotherapy with OX or various IRI formulations appears to improve PFS compared with single-agent FP. FPIRI, but not FPOX, appears to confer an OS advantage. The combination of FP with irinotecan formulations appears to be the appropriate next line of treatment upon progression after gemcitabine-based chemotherapy regimens. Cancer 2017;123:4680-6. V C 2017 American Cancer Society.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related deaths in the United States, with a 5-year survival rate of 2%. 1 Conventional cytotoxic chemotherapy remains the standard for treating patients with advanced disease. Based on 2 large, randomized phase 3 trials, combined folinic acid (leucovorin [LV]), 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (FOLFIRINOX) and combined gemcitabine plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel) have become the new standards for the first-line treatment of metastatic pancreatic cancer. Both regimens have exhibited a clinically meaningful advantage over gemcitabine monotherapy. [2] [3] [4] Various second-line therapies have been studied and are associated with improved survival outcomes in patients with metastatic pancreatic cancer who have experienced progression on gemcitabine-based regimens. Primarily, fluoropyrimidine (FP)-based regimens have been widely investigated in the second-line setting, [5] [6] [7] [8] [9] [10] In NAPOLI-1 (study of MM-398 [nanoliposomal irinotecan] with or without 5-FU/LV vs 5-FU/LV in patients with metastatic pancreatic cancer), a large, randomized, phase 3 trial, the combination of 5-FU and nanoliposomal irinotecan (nal-IRI) demonstrated a significant survival advantage compared with 5-FU monotherapy. 10 Based on these findings, the US Food and Drug Administration recently approved the combination of 5-FU and nal-IRI for the treatment of patients with refractory, metastatic pancreatic cancer. Although nal-IRI is established as an effective therapeutic option in the refractory setting versus FP monotherapy, the role of oxaliplatin is less clear because of the discordant results from 2 phase 3 trials investigating the combination versus FP monotherapy. 5, 7 The CONKO-003 trial demonstrated improved survival in patients who received combined oxaliplatin, LV, and 5-FU (OFF) compared with those who received 5-FU/LV. Conversely, results from the PANCREOX study suggested a potential detriment from the addition of oxaliplatin. Herein, we conducted a systematic review and meta-analysis of the currently available randomized controlled studies (RCTs) to determine the efficacy of adding irinotecan formulations or oxaliplatin to FPs in patients with PDAC after progression on gemcitabine-based therapy.
MATERIALS AND METHODS
The current study was performed by following procedures recommended by the Cochrane Collaboration and is reported in accordance with the recommendations set forth by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. 11 The outcomes of interest were overall survival (OS) and progression-free survival (PFS).
Information Sources and Search Methods
The primary objective of this meta-analysis was to determine the efficacy of combining an FP with oxaliplatin (FPOX) or various irinotecan formulations (FPIRI) as second-line therapy in patients with PDAC. A comprehensive literature search was conducted through January 2017 with the electronic databases MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) for relevant abstracts and titles. We included both phase 2 and phase 3 RCTs. The following are examples of the terms we used to identify studies of interest: "pancreatic adenocarcinoma," "metastatic pancreatic adenocarcinoma," and "second-line treatment."
Two individual reviewers (M.B.S. and B.F.) identified articles that were eligible for further review by screening the available abstracts and titles. If a study was deemed relevant, then it was obtained and reviewed. The proceedings of international conferences were also screened to identify upcoming clinical trials or studies of interest. The final search identified 5 studies reported in 4 full articles and 1 abstract presentation that met the inclusion criteria (Fig. 1) .
Data Collection and Extraction
Prespecified data elements were extracted from each trial, including patient demographics, baseline characteristics, study design, sample size, outcome measures, and other study characteristics (Table 1) . 5, 7, 10, 12 Two reviewers extracted the data from the included studies, and disagreements were resolved by referring to a third reviewer. The number of events in each trial was extracted, when available, based on the intention-to-treat approach.
Risk-of-Bias Assessment
The methodologic quality of RCTs was assessed using the Cochrane risk-of-bias tool. 13 Two reviewers independently assessed trial quality by examining several components: generation of allocation; concealment of allocation; blinding of participants, caregivers, data collectors, and outcome assessors; incomplete outcome data; and any other potential source of bias. Disagreements between the reviewers were resolved by discussion or were arbitrated with a third coauthor.
Statistical Analysis
Analyses were conducted using features on RevMan version 5.2 (The Nordic Cochrane Center, Copenhagen, Denmark). We calculated the relative risk (RR) from the abstracted data using the inverse variance method for each study outcome to allow for pooling of similar outcomes. We conducted random-effects meta-analyses using the DerSimonian and Laird method to pool treatment effects from included studies. 14 We chose the random effects method as primary analysis because of its conservative summary estimate and incorporation of between-study and within-study variance. We used the I 2 statistic to assess for heterogeneity across the included studies. The P value threshold for statistical significance was set at .05 for effect sizes.
RESULTS
In total, 550 titles and abstracts were identified by the screening electronic search strategy, of which 32 full-text articles met the eligibility for assessment. Five RCTs met the inclusion criteria evaluating FPOX/FPIRI versus FP in patients with PDAC ( Fig. 1 , Table 1) . 5, 7, 10, 12 The main reason for exclusion was lack of a control arm. The 5 studies included a total of 895 enrolled patients. Pertinent toxicities are described in Supporting Table 1 (see online  supporting 
information).

Interventions
Three studies (532 patients) that compared the combination of FP with oxaliplatin versus single-agent FP were identified (Table 1) . 5-FU was the FP used in 2 studies, whereas the oral agent S-1 was used in the third study. Oxaliplatin was combined with 5-FU using the modified FOLFOX6 regimen in PANCREOX study and the OFF regimen in CONKO-003. The efficacy of adding various irinotecan formulations to FP was evaluated in 2 studies (363 patients) ( Table 1 ). Mizuno et al investigated the combination of irinotecan and S-1 compared with S-1 monotherapy.
12 NAPOLI-1, a large, randomized phase 3 trial, investigated the combination of nanoliposomal formulation of irinotecan (nal-IRI) with 5-FU compared with single-agent 5-FU. 10 
FPOX versus FP
A meta-analysis of the 3 studies that evaluated the efficacy of FPOX combination versus FP demonstrated a modest improvement in PFS (hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.67-0.97; I 2 5 5%; P 5 .02). This benefit in PFS did not translate into a survival advantage (HR,1.03; 95% CI, 0.64-1.67; I 2 5 83%; P 5 .90) (Fig.  2) . Whereas the CONKO-003 trial demonstrated an improvement in OS among patients who received OFF versus those who received 5-FU (5.9 vs 3.3 months; HR, 0.66; P 5 .010), the PANCREOX study indicated that the patients assigned to FOLFOX had an inferior OS compared with those randomized to receive 5-FU monotherapy (6.1 vs 9.9 months; HR, 1.78; P 5 .02). Conversely, the study by Ohkawa et al did not demonstrate any significant difference between S-1 plus oxaliplatin (SOX) and S-1 in terms of OS (7.4 vs 6.9 months; HR, 1.03; P 5 .82).
FPIRI versus FP
Two studies evaluated the efficacy of FPIRI versus FP in patients with PDAC. A meta-analysis of these studies revealed an improvement in both PFS (HR, 0.64; 95% CI, 0.47-0.87; P 5 .005) and OS (HR, 0.70; 95% CI, 0.55-0.89; P 5 .004) in patients wo received the combination (Fig. 2) .
FPOX/FPIRI versus FP
The addition of oxaliplatin or an irinotecan formulation to an FP significantly improved PFS (HR. 0.74; 95% CI, 0.62-0.89; I 2 5 34%; P 5 .001). Although there was a Individual studies that included baseline characteristics and response rates are described.
Original Article trend toward an improvement in OS with the FPOX/ FPIRI combination compared with single-agent FP, it was not statistically significant (HR, 0.88; 95% CI, 0.65-1.19; I 2 5 74%; P 5 .39) (Fig. 2) .
Risk-of-Bias Assessment
The qualitative assessment was performed by assessing various indicators of each individual study based on the aforementioned tools of risk of bias and quality assessment, and the overall quality of the body of evidence was low to moderate. Supporting Table 2 (see online supporting information) and Figure 3 describe the methodological quality of the eligible studies in this systematic review.
DISCUSSION
There is paucity of data regarding the best available second-line treatment after progression on gemcitabinebased regimens in metastatic pancreatic adenocarcinoma. Although nal-IRI is now approved as the de facto secondline regimen in treatment-refractory, metastatic pancreatic cancer, there are conflicting data regarding the utility of oxaliplatin in this setting. The benefit of adding nal-IRI to an FP has been confirmed by the NAPOLI-1 trial, in which it demonstrated a significant improvement in OS and PFS compared with FP monotherapy. That study resulted in US Food and Drug Administration approval of the combination for patients with gemcitabinerefractory, metastatic pancreatic cancer. 10 Similar findings have been reported with the addition of irinotecan to S-1 in patients with treatment-refractory, metastatic pancreatic cancer. 12 Conversely, the benefit of adding oxaliplatin to FP backbone is more ambiguous.
We conducted a systematic review and meta-analysis and identified 5 RCTs (895 patients) that evaluated the addition of oxaliplatin or irinotecan formulations to FPs. Our results indicated that the addition of oxaliplatin or irinotecan to FP resulted in an improvement in PFS. However, these findings did not translate into improved OS with oxaliplatin-based regimens.
Three studies examined the role of oxaliplatin in treatment-refractory, metastatic pancreatic cancer compared with FP monotherapy and produced 3 different findings. [5] [6] [7] Although CONKO-003 demonstrated an improvement in the survival of patients who received OFF compared with 5-FU/LV (5.9 vs 3.3 months; HR, 0.66; P 5 .010), the PANCREOX study suggested a potential detrimental effect from the addition of oxaliplatin, as patients who were randomized to receive 5-FU/LV monotherapy had improved OS (6.1 vs 9.9 months; HR, 1.78; P 5 .02). Several factors may have contributed to these discordant results. In PANCREOX, patients who received 5-FU monotherapy had a median OS that was significantly longer compared with that observed in the 5-FU/LV historical control arm (Table 1 ). In addition, the baseline characteristics suggested an imbalance, in which the median time since diagnosis was significantly longer in the combination arm (7.9 months) compared with the monotherapy arm (5.7 months). Furthermore, an imbalance in the baseline performance status between the 2 arms could have influenced patient outcomes, in which a greater proportion of patients with an Eastern Cooperative Oncology Group performance status of 0 were randomized to the 5-FU monotherapy arm. This was reflected in the percentage of patients that received additional lines of treatment, because 23% of patients randomized to the 5-FU monotherapy arm received additional treatment compared with 7% of those in the FOL-FOX arm.
A more recent study assessing FOLFOX in patients after progression on gemcitabine was reported by Chung et al. 14 In that phase 2, randomized Southwest Oncology Group study (SWOG S115), patients were randomized to receive FOLFOX versus selumetinib (a mitogenactivated protein kinase kinase [MEK] inhibitor) plus the novel protein kinase C inhibitor MK-2206. The results from that study continue to suggest a less than interesting activity (at least PFS) with FOLFOX, confirming the overall results of our current analysis (Table 2) . 7, 10, 14 To our knowledge, this is the only available metaanalysis directly comparing a FPIRI/FPOX regimen with FP monotherapy. Vogel and colleagues published a review and planned on performing an indirect treatment comparison assessing similar outcomes; however, they concluded that the dissimilarity across the trials precluded them from conducting an indirect treatment comparison. 15 Our meta-analysis includes the comprehensive nature of the literature search that provided the best available evidence examining 3 specific aims: 1) Is FPOX/ FPIRI better than FP monotherapy? 2) Is FPIRI better than FP? and 3) Is FPOX better than FP? While acknowledging the limitations of our meta-analysis, the primary limitation of our investigation is the relatively small number (n 5 5) of randomized studies available for analysis. This led to an analysis that was more prone to heterogeneity, which was mostly manifested in the OS data from FPIRI versus FP monotherapy (I 2 5 83%) for the reasons discussed above. In addition, the different treatment interventions used across these studies also potentially could have contributed to the differing findings.
Conclusion
In conclusion, the combination of oxaliplatin or various irinotecan formulations resulted in an improvement in PFS over single-agent FPs. The combination of FP with an irinotecan formulation, but not with oxaliplatin, seems to confer an OS advantage. Oxaliplatin with FP after gemcitabine failure may need further confirmatory studies to establish its role in refractory pancreatic cancer. Until then, the combination of FP with irinotecan formulations, specifically 5-FU/nal-IRI, with the phase 3 evidence, appears to be the appropriate next line of treatment upon progression after gemcitabine-based chemotherapy regimens. 
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